Telix at ASCO GU 2023

10 February 2023

ASCO GU (February 16-18, 2023), the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present results of the Phase III ZIRCON study ( Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC).

The program will also include six presentations on Telix’s carbonic anhydrase IX (CAIX)- and prostate specific membrane antigen (PSMA)-targeting theranostic candidates. Presentations will report on advancements in positron emission tomography (PET) imaging of prostate cancer with 68Ga PSMA-11; the potential utility of TLX250-CDx in tumour types beyond ccRCC; and the STARLITE Phase II studies, which are assessing the efficacy of TLX250 (177Lu-DOTA-girentuximab) targeted radiation in combination with immunotherapy for ccRCC. 

ASCO GU presentation details are as follows: 

Session: Oral Abstract Session C: Renal and Rare Tumors 

Title: Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON) 

Date and Time: 18-Feb-2023, 2:00 PM-3:30 PM 

Presenter: Brian Shuch (UCLA) 

Abstract ID: LBA602  

Poster Session B: Prostate Cancer and Urothelial Carcinoma 
Date and Time: 17-Feb-2023, 12:30 PM-2:00 PM & 5:15 PM-6:15 PM 

Title: 68Ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly Study) – Preliminary Results.” 

Presenter: Bradley, Olivia (Tulane Cancer Center); senior author: Oliver Sartor (Tulane Cancer Center) 

Abstract ID: 54 Identifier: NCT04854369 

Title: “Ga-68 PSMA-11 (Illuccix) impacting prostate cancer management in a real-world setting: a pilot experience using the total-body PET/CT scanner (uExplorer).” 

Presenter: Hashad Kulkarni (BAMF Health) 

Abstract ID: 62 

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers 
Date and Time: 18-Feb-23, 07:00 AM-08:00 AM & 12:30 PM-2:00 PM  

Title: 89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX” (STARBURST study)” 

Presenter: Amol Talkalkar (Emory) 

Abstract ID: TPS738 Identifier: NCT05563272 

Title: “Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC” (STARLITE 1 study) 

Presenter: Elshad Hasanov (MD Anderson Cancer Center) 

Abstract ID: TPS749 

Title: “Phase 2 Study of Nivolumab plus 177Lutetium-labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-girentuximab) in Patients (pts) with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)” (STARLITE 2 study) 

Presenter: Darren Feldman (Memorial Sloan Kettering Cancer Center) 

Abstract ID: TPS752 Identifier: NCT05239533